Drug: Winrevair (sotatercept)

Manufacturer: Merck

Route of Administration: Subcutaneous

Site of Care: Outpatient

Approved Indication: treatment of adults with pulmonary arterial hypertension (PAH, WHO group 1) to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events

Disease: pulmonary arterial hypertension

Therapeutic Area: Pulmonary

Enrollment Form Link: Merck Access Program – Winrevair

Phone Number: 888-637-2502

Fax Number: 877-219-7579

Product Website: winrevair.com